Jasper Therapeutics, Inc. reported positive outcomes from its SPOTLIGHT Phase 1b/2a study of briquilimab for chronic inducible urticaria, with results presented at the EAACI Annual Congress. In the 180mg cohort comprising 12 participants, 92% achieved a complete response, and 100% demonstrated a clinical response. The treatment showed significant reductions in tryptase levels, with no serious adverse events recorded, indicating a favorable safety profile.
The trial showed that by week 8, 58% maintained a clinical response, and the treatment was well tolerated, with only mild decreases in neutrophil counts that resolved quickly. Jasper plans to discuss these findings further during a conference call on June 16, 2025.
Notably, the study included a small participant size, which raises questions about the broader applicability of the results. Jasper Therapeutics continues to explore briquilimab’s efficacy and safety as it focuses on developing treatments for mast cell-driven diseases.
